AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
(d) Election of Directors
On December 7, 2018, the Board of Directors of Avadel Pharmaceuticals plc (the “Company”), acting on the recommendation of its Nominating and Corporate Governance Committee, unanimously appointed Mr. Kevin Kotler to the Company’s Board of Directors, effective immediately. Mr. Kotler’s term will expire at the Company’s 2019 Annual General Meeting of Shareholders. Concurrent with his appointment as a director, Mr. Kotler was also appointed to the Board’s Compensation Committee and Nominating and Corporate Governance Committee. He will be compensated to the same arrangements as the Company’s other non-management directors, with his cash compensation pro-rated to reflect the partial term he will serve through the Company’s 2019 Annual General Meeting of Shareholders. Compensation arrangements for directors are described under the heading “Director Compensation” in the Company’s 2018 Proxy Statement.
There are no arrangements or understandings between Mr. Kotler and any other person to which Mr. Kotler was appointed to serve on the Board. Mr. Kotler has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.
On December 11, 2018, the Company issued a press release announcing the appointment of Mr. Kotler to the Company’s Board of Directors. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press release of Avadel Pharmaceuticals plc dated December11,2018|
AVADEL PHARMACEUTICALS PLC ExhibitEX-99.1 2 tv508706_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors DUBLIN,…To view the full exhibit click